Skip to main content
Erschienen in: Drugs & Aging 3/2008

01.03.2008 | Leading Article

Use of Gabapentin in the Treatment of Behavioural and Psychological Symptoms of Dementia

A Review of the Evidence

verfasst von: Yunie Kim, Kirsten M. Wilkins, Dr Rajesh R. Tampi

Erschienen in: Drugs & Aging | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Behavioural and psychological symptoms of dementia (BPSD) have been defined as a heterogeneous range of psychological reactions, psychiatric symptoms and behaviours that may be unsafe, disruptive and impair the care of a patient in a given environment. To date, there are no US FDA-approved drugs or clear standards of pharmacological care for the treatment of BPSD. The novel antiepileptic agent gabapentin is being increasingly considered for use in the geriatric population because of its relatively favourable safety profile compared with other classes of psychiatric medications. Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia. It has also been reported to be successful in the treatment of a 13-year-old boy with behavioural dyscontrol, a finding that suggested a possible role for gabapentin in the treatment of other behavioural disorders. The purpose of this review was to find evidence for the use of gabapentin in the treatment of BPSD. To this end, a search was performed for case reports, case series, controlled trials and reviews of gabapentin in the treatment of this condition. The key words ‘dementia’, ‘Alzheimer’s disease’ and ‘gabapentin’ were used. Searches were performed in PubMed, PsycINFO, Ovid MEDLINE, Cochrane Library and ClinicalTrials.gov. The search revealed that there are limited data on the efficacy of gabapentin for BPSD in the form of 11 case reports, 3 case series and 1 retrospective chart review; no controlled studies appear to have been published to date on this topic. In most of the reviewed cases, gabapentin was reported to be a well tolerated and effective treatment for BPSD. However, two case reports in which gabapentin was used in the context of agitation in dementia with Lewy bodies questioned the appropriateness of gabapentin for all types of dementia-related agitation. The dearth of available data limits support for the off-label use of gabapentin for the treatment of BPSD. Furthermore, controlled studies should be conducted before gabapentin can be clinically indicated for the successful treatment of BPSD.
Literatur
1.
Zurück zum Zitat Bharucha AJ, Rosen J, Mulsant BH, et al. Assessment of behavioral and psychological symptoms of dementia. CNS Spectr 2002; 7(11): 797–802PubMed Bharucha AJ, Rosen J, Mulsant BH, et al. Assessment of behavioral and psychological symptoms of dementia. CNS Spectr 2002; 7(11): 797–802PubMed
2.
Zurück zum Zitat Jackson-Siegal JM, Siegal AP. Improving elderly patient outcomes: anticonvulsants in agitation. Geriatrics 2002; 57(9): Suppl 5–8 Jackson-Siegal JM, Siegal AP. Improving elderly patient outcomes: anticonvulsants in agitation. Geriatrics 2002; 57(9): Suppl 5–8
3.
Zurück zum Zitat Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293(5): 596–608PubMedCrossRef Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293(5): 596–608PubMedCrossRef
4.
Zurück zum Zitat Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opin Drug Saf 2007; 6(2): 133–45PubMedCrossRef Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opin Drug Saf 2007; 6(2): 133–45PubMedCrossRef
5.
Zurück zum Zitat Moretti R, Torre P, Antonello RM, et al. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 2003; 20(14): 1035–40PubMedCrossRef Moretti R, Torre P, Antonello RM, et al. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 2003; 20(14): 1035–40PubMedCrossRef
6.
Zurück zum Zitat Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRef Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRef
7.
Zurück zum Zitat Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD003476 Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD003476
8.
Zurück zum Zitat Tariot PN, Raman R, Jaimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005 Nov; 13(11): 942–9PubMed Tariot PN, Raman R, Jaimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005 Nov; 13(11): 942–9PubMed
9.
Zurück zum Zitat Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9(1): 58–66PubMed Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9(1): 58–66PubMed
10.
Zurück zum Zitat Tariot PN, Schneider LS, Mintzer JE. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a doubleblind, placebo-controlled trial. CurrTher Res 2001 Jan; 62(1): 51–67 Tariot PN, Schneider LS, Mintzer JE. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a doubleblind, placebo-controlled trial. CurrTher Res 2001 Jan; 62(1): 51–67
11.
Zurück zum Zitat Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behaviour in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002 Jun; 17(6): 579–85PubMedCrossRef Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behaviour in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002 Jun; 17(6): 579–85PubMedCrossRef
12.
Zurück zum Zitat Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006; 23(11): 877–86PubMedCrossRef Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006; 23(11): 877–86PubMedCrossRef
13.
Zurück zum Zitat Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8Suppl. 1: S28–39PubMedCrossRef Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8Suppl. 1: S28–39PubMedCrossRef
14.
Zurück zum Zitat Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54–61PubMed Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54–61PubMed
15.
Zurück zum Zitat Olin JT, Fox JS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9(4): 400–5PubMed Olin JT, Fox JS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9(4): 400–5PubMed
16.
Zurück zum Zitat Lanctot KL, Herrmann N, Rothenburg L, et al. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49(7): 439–53PubMed Lanctot KL, Herrmann N, Rothenburg L, et al. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49(7): 439–53PubMed
17.
Zurück zum Zitat Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005; 19(1): 23–8PubMedCrossRef Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005; 19(1): 23–8PubMedCrossRef
18.
Zurück zum Zitat Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15(1): 84–7PubMedCrossRef Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15(1): 84–7PubMedCrossRef
19.
Zurück zum Zitat Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging 2006; 27(8): 1110–7PubMedCrossRef Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging 2006; 27(8): 1110–7PubMedCrossRef
20.
Zurück zum Zitat Lanctot KL, Herrmann N, Rothenburg L, et al. Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int Psychogeriatr 2007; 19(1): 151–8PubMedCrossRef Lanctot KL, Herrmann N, Rothenburg L, et al. Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int Psychogeriatr 2007; 19(1): 151–8PubMedCrossRef
22.
Zurück zum Zitat Vieta E, Manuel Goikolea J, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006; 67(3): 473–7PubMedCrossRef Vieta E, Manuel Goikolea J, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006; 67(3): 473–7PubMedCrossRef
23.
Zurück zum Zitat Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41(2): 119–28PubMedCrossRef Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41(2): 119–28PubMedCrossRef
24.
Zurück zum Zitat Choudhuri I, Sarvanathan N, Gottlob I. Survey of management of acquired nystagmus in the United Kingdom. Eye 2007; 21(9): 1194–7PubMedCrossRef Choudhuri I, Sarvanathan N, Gottlob I. Survey of management of acquired nystagmus in the United Kingdom. Eye 2007; 21(9): 1194–7PubMedCrossRef
25.
Zurück zum Zitat Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366(9488): 818–24PubMedCrossRef Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366(9488): 818–24PubMedCrossRef
26.
Zurück zum Zitat Reddy SY, Warner H, Guttuso Jr T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108(1): 41–8PubMedCrossRef Reddy SY, Warner H, Guttuso Jr T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108(1): 41–8PubMedCrossRef
27.
Zurück zum Zitat Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19(12): 3137–9PubMedCrossRef Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19(12): 3137–9PubMedCrossRef
28.
Zurück zum Zitat Manenti L, Vaglio A, Costantino E, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005; 18(1): 86–91PubMed Manenti L, Vaglio A, Costantino E, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005; 18(1): 86–91PubMed
29.
Zurück zum Zitat Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet 2006; 45(11): 1061–75PubMedCrossRef Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet 2006; 45(11): 1061–75PubMedCrossRef
30.
Zurück zum Zitat Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with post-herpetic neuralgia. Am J Geriatr Pharmacother 2004; 2(3): 157–62PubMedCrossRef Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with post-herpetic neuralgia. Am J Geriatr Pharmacother 2004; 2(3): 157–62PubMedCrossRef
31.
Zurück zum Zitat Laroche S. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007; 13(3): 133–9PubMedCrossRef Laroche S. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007; 13(3): 133–9PubMedCrossRef
32.
Zurück zum Zitat Bookwalter T, Gitlin M. Gabapentin-induced neurologic toxicities. Pharmacotherapy 2005; 25(12): 1817–9PubMedCrossRef Bookwalter T, Gitlin M. Gabapentin-induced neurologic toxicities. Pharmacotherapy 2005; 25(12): 1817–9PubMedCrossRef
33.
Zurück zum Zitat Parke-Davis. Neurontin (gabapentin) [package insert]. New York: Parke-Davis, 2005 Parke-Davis. Neurontin (gabapentin) [package insert]. New York: Parke-Davis, 2005
34.
Zurück zum Zitat Sethi MA, Mehta R, Devanand DP. Gabapentin in geriatric mania. J Geriatr Psychiatr Neurol 2003; 16(2): 117–20CrossRef Sethi MA, Mehta R, Devanand DP. Gabapentin in geriatric mania. J Geriatr Psychiatr Neurol 2003; 16(2): 117–20CrossRef
35.
Zurück zum Zitat Robillard M, Conn D. Gabapentin use in geriatric patients with depression and bipolar illness [letter]. Can J Psychiatry 2001; 46(8): 764PubMed Robillard M, Conn D. Gabapentin use in geriatric patients with depression and bipolar illness [letter]. Can J Psychiatry 2001; 46(8): 764PubMed
36.
Zurück zum Zitat Ryback R, Ryback L. Gabapentin for behavioral dyscontrol [letter]. Am J Psychiatry 1995; 152(9): 1399PubMed Ryback R, Ryback L. Gabapentin for behavioral dyscontrol [letter]. Am J Psychiatry 1995; 152(9): 1399PubMed
37.
Zurück zum Zitat Regan WM, Gordon SM. Gabapentin for behavioral agitation in Alzheimer’s disease. J Clin Psychopharmacol 1997; 17(1): 59–60PubMedCrossRef Regan WM, Gordon SM. Gabapentin for behavioral agitation in Alzheimer’s disease. J Clin Psychopharmacol 1997; 17(1): 59–60PubMedCrossRef
38.
Zurück zum Zitat Sheldon LJ, Ancill RJ, Holliday SG. Gabapentin in geriatric psychiatry patients. Can J Psychiatry 1998; 43(4): 422–3PubMed Sheldon LJ, Ancill RJ, Holliday SG. Gabapentin in geriatric psychiatry patients. Can J Psychiatry 1998; 43(4): 422–3PubMed
39.
Zurück zum Zitat Goldenberg G, Kahaner K, Basavaraju N, et al. Gabapentin for disruptive behaviour in an elderly demented patient. Drugs Aging 1998; 13(2): 183–4PubMedCrossRef Goldenberg G, Kahaner K, Basavaraju N, et al. Gabapentin for disruptive behaviour in an elderly demented patient. Drugs Aging 1998; 13(2): 183–4PubMedCrossRef
40.
Zurück zum Zitat Low Jr RA, Brandes M. Gabapentin for the management of agitation. J Clin Psychopharmacol 1999 Oct; 19(5): 482–3PubMedCrossRef Low Jr RA, Brandes M. Gabapentin for the management of agitation. J Clin Psychopharmacol 1999 Oct; 19(5): 482–3PubMedCrossRef
41.
Zurück zum Zitat Herrmann N, Lanctot K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000; 20(1): 90–3PubMedCrossRef Herrmann N, Lanctot K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000; 20(1): 90–3PubMedCrossRef
42.
Zurück zum Zitat Hawkins JW, Tinklenberg JR, Sheikh JI, et al. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000; 8(3): 221–5PubMed Hawkins JW, Tinklenberg JR, Sheikh JI, et al. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000; 8(3): 221–5PubMed
43.
Zurück zum Zitat Dallocchio C, Buffa C, Mazzarello P. Combination of donepezil and gabapentin for behavioral disorders in Alzheimer’s disease [letter]. J Clin Psychiatry 2000 Jan; 61(1): 64PubMedCrossRef Dallocchio C, Buffa C, Mazzarello P. Combination of donepezil and gabapentin for behavioral disorders in Alzheimer’s disease [letter]. J Clin Psychiatry 2000 Jan; 61(1): 64PubMedCrossRef
44.
Zurück zum Zitat Roane DM, Feinberg TE, Meckler L, et al. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000; 12(1): 40–3PubMed Roane DM, Feinberg TE, Meckler L, et al. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000; 12(1): 40–3PubMed
45.
Zurück zum Zitat Miller LJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001; 35(4): 427–31PubMedCrossRef Miller LJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001; 35(4): 427–31PubMedCrossRef
46.
Zurück zum Zitat Moretti R, Torre P, Antonello RM, et al. Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients. Eur J Neurol 2001; 8(5): 501–2PubMedCrossRef Moretti R, Torre P, Antonello RM, et al. Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients. Eur J Neurol 2001; 8(5): 501–2PubMedCrossRef
47.
Zurück zum Zitat Rossi P, Serrao M, Pozzessere G. Gabapentin-induced worsening of neuropsychiatric symptoms in dementia with Lewy bodies: case reports. Eur Neurol 2002; 47(1): 56–7PubMedCrossRef Rossi P, Serrao M, Pozzessere G. Gabapentin-induced worsening of neuropsychiatric symptoms in dementia with Lewy bodies: case reports. Eur Neurol 2002; 47(1): 56–7PubMedCrossRef
48.
Zurück zum Zitat Alkhalil C, Hahar N, Alkhalil B, et al. Can gabapentin be a safe alternative to hormonal therapy in the treatment of inappropriate sexual behavior in demented patients?. Int Urol Nephrol 2003; 35(2): 299–302PubMedCrossRef Alkhalil C, Hahar N, Alkhalil B, et al. Can gabapentin be a safe alternative to hormonal therapy in the treatment of inappropriate sexual behavior in demented patients?. Int Urol Nephrol 2003; 35(2): 299–302PubMedCrossRef
49.
Zurück zum Zitat Alkhalil C, Tanvir F, Alkhalil B, et al. Treatment of sexual disinhibition in dementia: case reports and review of the literature. Am J Ther 2004; 11(3): 231–5PubMedCrossRef Alkhalil C, Tanvir F, Alkhalil B, et al. Treatment of sexual disinhibition in dementia: case reports and review of the literature. Am J Ther 2004; 11(3): 231–5PubMedCrossRef
50.
Zurück zum Zitat Raudino F, Mascalzi MG, Zagami A. Gabapentin and behavioral disorders in severe Alzheimer disease. J Clin Psychopharmacol 2004; 24(4): 459–60PubMedCrossRef Raudino F, Mascalzi MG, Zagami A. Gabapentin and behavioral disorders in severe Alzheimer disease. J Clin Psychopharmacol 2004; 24(4): 459–60PubMedCrossRef
52.
Zurück zum Zitat Dogukan A, Aygen B, Berilgen MS, et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006; 10(2): 168–9PubMedCrossRef Dogukan A, Aygen B, Berilgen MS, et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006; 10(2): 168–9PubMedCrossRef
Metadaten
Titel
Use of Gabapentin in the Treatment of Behavioural and Psychological Symptoms of Dementia
A Review of the Evidence
verfasst von
Yunie Kim
Kirsten M. Wilkins
Dr Rajesh R. Tampi
Publikationsdatum
01.03.2008
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 3/2008
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825030-00002

Weitere Artikel der Ausgabe 3/2008

Drugs & Aging 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.